Novartis Acquires Mutant-Selective PI3Kα Inhibitor to Enhance Breast Cancer Treatment Options
Novartis has agreed to acquire SNV4818, a pan-mutant-selective PI3Kα inhibitor from Synnovation Therapeutics, targeting PIK3CA mutations in hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. This oral agent, in Phase 1/2 trials for breast cancer and solid tumors, selectively inhibits mutant PI3Kα prevalent in 40% of HR+/HER2- patients while sparing wild-type forms to improve tolerability.
Precision Strike on PIK3CA Mutations
Novartis’ acquisition of the mutant-selective PI3Kα inhibitor SNV4818, bolsters its HR+/HER2- breast cancer pipeline. The agent’s novel chemistry targets mutated PI3Kα in tumors, overcoming limitations of non-selective inhibitors that cause dose-limiting toxicities. Preclinical data show strong activity against common PIK3CA mutations with high selectivity, enabling better dosing, combinations with CDK inhibitors and endocrine therapies, and improved outcomes for patients with worse prognoses.
This mutant-selective PI3Kα inhibitor addresses key tolerability barriers, as noted by Novartis’ President of Development Shreeram Aradhye, M.D. It preserves normal PI3Kα function, supporting evaluation in ongoing Phase 1/2 trials for HR+/HER2- breast cancer and solid tumors. This approach advances precision oncology by translating PIK3CA biology into targeted therapies distinct from broader inhibitors.
Deal Terms Fuel Oncology Expansion
Novartis’ 30+ years of oncology leadership underpin this move, integrating the mutant-selective PI3Kα inhibitor with existing CDK and endocrine therapies. The transaction includes a $2 billion upfront payment to Pikavation Therapeutics (a Synnovation subsidiary) plus up to $1 billion in milestones, with closure expected in H1 2026 pending approvals. It targets unmet needs in 40% of PIK3CA-mutated HR+/HER2- cases through Phase 1/2 data.
